Bharat Serums and Vaccines Limited (BSV) was set up in 1971 to pursue an ambitious goal of introducing specialized healthcare products to meet the needs of a quality conscious market. The company has been manufacturing and marketing biological, pharmaceutical and biotechnology products, ever since.

Today, BSV holds a formidable market share in India for plasma derivatives, and is constantly expanding its range of products by introducing new and improved therapies based on strong R&D initiatives and efforts.

Information on:
  • Sepsis is the body’s systemic inflammatory and coagulopathic response to microbial infection (in the blood, urine, lungs, skin, or other tissues) that often progresses to a severe form manifested by multiple organs.
  • Sepsis is regarded as one of the leading causes of death throughout the world.
  • India’s First Ulinastatin containing formulation for Sepsis Management.
    U-Tryp provides the following benefits in Sepsis:
    • Reduces mortality in severe sepsis patients.
    • Reduces duration of mechanical ventilation and hospital stay thus reducing cost of care
Sepsis Experience Exchange and Development
  • SEED is a forum for the doctors to exchange their experiences, latest developments and advances in the area of Sepsis management.
  • To know about it kindly get your self registered with SEED.